Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723878 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL1726230 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL1723692 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL29859252 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL14353631 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL1723696 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL3631759 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| SCHEMBL1725094 | 1.00 | TSHR (0.59) | TSHRALDH1A1TDP1MAPTMMP3 | |
| Hydrochloric Acid SCHEMBL27893126 | 0.99 | TSHR (0.61) | TSHRALDH1A1TDP1MAPTMMP3 | |
| Hydrochloric Acid SCHEMBL19064539 | 0.99 | TSHR (0.61) | TSHRALDH1A1TDP1MAPTMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192470-A1 | METHOD OF TREATING GLIOBLASTOMA OR OTHER CANCERS EXPRESSING P75 NEUROTROPHIN RECEPTOR | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-09-26 | — | — | WO | claimed |
| EP-3470402-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | Pharmatrophix Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| US-20140100224-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-04-10 | — | — | US | claimed |
| US-20130005731-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. (US) | 2013-01-03 | — | — | US | claimed |
| EP-2403839-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | The University of North Carolina At Chapel Hill (US) | 2012-01-11 | — | — | EP | claimed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | claimed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | claimed |
| WO-2024192470-A1 | METHOD OF TREATING GLIOBLASTOMA OR OTHER CANCERS EXPRESSING P75 NEUROTROPHIN RECEPTOR | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-09-26 | — | — | WO | disclosed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3470402-B1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2403839-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | The University of North Carolina At Chapel Hill (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| WO-2011060262-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-20140100224-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | TSHR 439/4885ALDH1A1 1890/4885TDP1 639/4885 |
| US-20130005731-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 885/4885ALDH1A1 4396/4885TDP1 1256/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | TSHR 439/4885ALDH1A1 1890/4885TDP1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.